Object. Given the feasibility of curative surgical and endovascular therapy for cerebral dural arteriovenous fistulas (DAVFs), there is a relative paucity of radiosurgical series for these lesions as compared with their arteriovenous malformation counterparts.
C
erebral DAVFs are vascular shunts fed by meningeal arteries located in the dura mater. 1, 11, 18 Symptomatic DAVFs with cortical venous drainage or reflux (CVD) portend a significant risk of hemorrhage and warrant surgical or endovascular intervention. 6, 8, 29, 31, 32 Dural AVFs without CVD are often observed, given their minute risk of hemorrhage; 6, 27 however, DAVFs associated with intractable symptoms without CVD and asymptomatic DAVFs with CVD generally merit treatment.
29,31
Unlike their AVM counterparts, surgically high risk or inaccessible DAVFs can often be cured via endovascular means. 17, 30, 33 As a result, radiosurgical series for DAVF in the literature are relatively sparse. Radiosurgery is ideally suited for poor surgical and/or endovascular candidates, including the elderly, patients with multiple comorbidities (particularly those with renal dysfunction), and patients with poor endovascular access. Herein, we present our own experience with SRS for DAVF and review the literature of radiosurgery for these lesions.
Methods
This study was approved by the local Brigham and Women's Hospital Institutional Review Board.
Fifty-six patients with 70 cerebral DAVFs were seen at our institution by our neurosurgery or interventional neuroradiology service from 2004 through 2010. Twenty-nine DAVFs were managed primarily surgically (41%), 18 were observed (26%), 13 were treated with embolization alone (19%), and 10 were managed with SRS (14%). One patient undergoing SRS was lost to follow-up, leaving 8 patients with 9 DAVFs for our analysis. Basic patient demographic characteristics, mode of presentation, DAVF location, DAVF drainage, and prior treatment are given in Table 1 .
On the day of radiosurgery, patients were placed in a stereotactic head frame under local anesthesia. They underwent cerebral angiography for lesion localization, followed by radiosurgery with a 6-MV linear accelerator (LINAC) with multileaf collimation. Patients were discharged on the day of treatment on an oral dexamethasone taper. Our patients are followed up via CTA or MRA every 6 months after treatment and annually thereafter for 3 years. Cerebral angiography is performed to confirm obliteration in patients with high-risk DAVFs at 3 years or when noninvasive imaging is suggestive of obliteration. For low-risk DAVFs, angiography is performed if noninvasive imaging does not demonstrate obliteration at 3 years.
For our literature review, a PubMed search was performed using the terms "arteriovenous fistula," "dural arteriovenous fistula," "dAVF," "SRS," and "radiosurgery." Identified publications were reviewed for obliteration rates, post-SRS hemorrhage rates, transient clinical worsening, and permanent clinical worsening at follow-up. We additionally extracted these parameters for DAVFs stratified by location and drainage pattern, gathering ample information about cavernous, transverse-sigmoid, and tentorial AVFs, as well as those with and without CVD. In cases of multiple reports derived from the same patient database, we used the most recent and inclusive study for analysis.
Statistical Methods
Statistical analysis was performed using the trend test when comparing multiple proportions, followed by the Fisher exact test. Pairwise p values were adjusted for multiple comparison using the Bonferroni correction.
Results
Eight patients with 9 DAVFs underwent radiosurgery at our institution over the past 6 years ( Table 1 ). The group included 5 men and 3 women; their mean age (± SD) was 56.8 ± 8.9 years (range 44-69 years). Four patients presented with hemorrhage from other vascular lesionsone with a basilar apex aneurysm, one with a surgically treated transverse-sigmoid DAVF, one with an AVM, and a fourth patient with rupture of moyamoya vessels. Three patients presented with tinnitus, and another patient had a DAVF that was discovered on screening MRI performed for a strong family history of ruptured cerebral aneurysms. There were 2 transverse-sigmoid and 2 tentorial DAVFs. One patient had an anterior cranial fossa DAVF, one an inferior petrosal sinus DAVF, one a superior sagittal sinus DAVF, and one had a jugular DAVF and a petrous apex DAVF. Three fistulas were classified as Borden Type I, 3 as Type II, and 3 as Type III. 6 No patients suffered from ischemic symptoms, hydrocephalus, progressive dementia, or hemorrhage due to their DAVF. Four of the DAVFs were treated with embolization prior to SRS.
The mean treatment volume was 1.0 cm 3 (range 0.10-2.94 cm 3 ). The lesions were treated with a mean dose of 17.7 Gy (range 15-20 Gy). After a mean follow-up period of 2.9 years (range 1.6-4.7 years), 8 (89%) of 9 DAVFs were radiographically obliterated. One patient had slight worsening of his tinnitus at 2.1-year follow-up with persistent flow in his transverse sinus DAVF. There were otherwise no complications of SRS and no hemorrhage was observed after SRS. Table 2 reviews the results of SRS for DAVFs across 14 studies (including our own). Five hundred forty-nine patients with 558 DAVFs were treated. Two hundred thirty-nine (45%) of the DAVFs had CVD. One hundred ninety-three (35%) were treated with adjunctive therapy, most often embolization. The mean marginal dose across these studies ranged from 16 to 25 Gy and the mean treated volume ranged from 0.8 to 9.6 cm 3 . The obliteration rate for 372 DAVFs reported across these series was 71% (263 of 372). The mean duration of follow-up ranged from 2 to 11.4 years, with transient deterioration observed in 9.1% of patients (50 of 549) and permanent worsening seen in 2.4% of patients (13 of 549), including 1 death from post-SRS hemorrhage (1 [0.2%] of 549). These figures include symptoms as a result of post-SRS hemorrhage that occurred in 1.6% of cases (9 of 558). Notably, there was a report of one case of de novo DAVF fistula development after SRS directed at another DAVF. 9 In addition, 2 cases of deafness were reported in association with DAVF obliteration; 16, 19 this phenomenon has also been seen with spontaneous closure of a DAVF. * ant = anterior; ASx = asymptomatic; Dose = margin dose; embo = embolization; FU = follow-up; HA = headache; IPS = inferior petrosal sinus; Norm = normalization; PTV = planned treatment volume; SSS = superior sagittal sinus; TS = transverse-sigmoid; Tx = treatment; VI = cranial nerve VI palsy. † An anterior inferior cerebellar artery feeding aneurysm was also obliterated. Detailed obliteration and complications rates stratified by DAVF location and drainage pattern are provided in Table 3 and summarized in Table 4 . Notably, obliteration rates were greater for cavernous DAVFs (84%) as compared with transverse-sigmoid (58%) and tentorial (59%) DAVFs (adjusted p values, p cav,TS = 1.98 × 10 -4 , p cav,tent = 0.032). They were also greater for DAVFs without CVD (80%, compared with 60% for those with CVD, p = 7.59 × 10 -4
14
). As expected, post-SRS hemorrhage was significantly more common for DAVFs with CVD-occurring in 4.8% of patients with CVD compared with 0.7% of patients without CVD. In fact, the one case of post-SRS hemorrhage occurring with a DAVF without CVD was postulated to occur independent of the DAVF.
22
This one case was also included in the 2 cases of post-SRS hemorrhage occurring after cavernous DAVF (258 cases) were treated; these fistulas have a slightly lower post-SRS hemorrhage rate than their transverse-sigmoid counterparts (0.8% vs 1.6%).
Patients with transvserse-sigmoid DAVFs had ostensibly lower rates of transient worsening after SRS than those with cavernous DAVFs (4.8% vs 9.3%, respectively); however permanent worsening, including 1 death, was more common in the transverse-sigmoid than the cavernous DAVF cohort (3.8% vs 1.9%, respectively). Not unexpectedly, post-SRS worsening of symptoms referable to the DAVF was less common for DAVFs without CVD (3.4% transient worsening, 0.9% permanent) than those with CVD (7.3% transient, 2.4% permanent).
Discussion
Radiosurgery dedicated to DAVF treatment followed early, scattered reports in the 1980s of successful conventional radiation treatment of these lesions. 5, 13 The first case series was reported by Barcia-Salorio et al. 3 in 1991, detailing 20 low-flow cavernous DAVFs with a 90% cure rate after a mean follow-up of only 7 months. Symptomatic improvement was noted as early as 2 months after treatment.
This expedient obliteration rate observed for DAVFs has been frequently reproduced, with some studies demonstrating symptomatic improvement as early as 1 month after treatment and obliteration as early as 3 months after treatment. 20 This may be a result of their proclivity to be small and low-flow. Although this would appear to make patients with DAVFs ideal candidates for radiosurgery, those with CVD have a much more malignant natural history and require expedient curative treatment via surgical or endovascular means. 6, 8, 29, 31, 32 Likewise, those without CVD with disabling symptoms should be treated with modalities leading to rapid symptomatic alleviation. Given the delayed clinical effect of radiosurgery, this essentially leaves it as an adjunctive therapy to embolization or as a stand-alone therapy when other means of treatment are not feasible. Our general treatment algorithm is provided in Fig. 1 . Patients in whom SRS fails after 30-36 months or who demonstrate clinical or radiographic recurrence are reconsidered for treatment in the same fashion according to this algorithm. Repeat SRS is a consideration for those lesions deemed unamenable to surgical or endovascular therapy. Infrequently addressed in our reviewed series, repeat SRS was successful in DAVF obliteration in 1 of 3 cases described. 9, 21 Similar to the results of SRS for AVMs, 24, 26 the general rate of obliteration across our literature review was 71%, with transient worsening seen in 9.1% of patients and permanent worsening seen in 2.4% of cases. Post-SRS hemorrhage only occurred in 1.6% of cases (4.8% of cases with CVD). Less frequent deficits seen at follow-up as well as greater obliteration rates for DAVFs without CVD (80%) underscore that those without CVD are significantly better candidates for SRS. Patients with symptomatic DAVFs without CVD are best treated initially with radiosurgery followed by early post-SRS embolization for expedient alleviation of symptoms. In one study of 20 cavernous DAVFs, the median time to symptomatic improvement decreased from 6 months to 2 weeks when embolization was used adjunctively with SRS. 25 It is ideal to perform radiosurgery first to ensure targeting of the entire lesion.
9,35
Although one study did not demonstrate a significant difference in obliteration rates for SRS in conjunction with embolization, 7 another demonstrated greater obliteration rates when these 2 modalities were used in conjunction.
35
Comprising the majority of DAVFs reported in the literature, low-flow (Barrow Types B-D) 4 cavernous DAVFs are ideal candidates for radiosurgery. 10, 12 Often unamenable to direct surgical cure and generally more challenging lesions for curative endovascular therapy, cavernous DAVFs often do not have CVD, 34 making them well suited for SRS. We demonstrated an overall obliteration rate of 84% for cavernous DAVFs, with lower rates of long-term worsening (1.9%). The SRS results for the treatment of direct AVFs (Barrow Type A) 4 were more sparse and generally more disappointing 2,28 than results of SRS when applied to Barrow Type D DAVFs (both external and internal carotid artery supply). 10, 12, 25 In one series in which SRS was applied for 3 partially treated high-flow shunts, obliteration was only seen in one case.
2
On the other hand, 20 (91%) of 22 low-flow fistulas in this series were obliterated in a mean time of 7.5 months.
Often preceding radiographic cure, 12, 22, 23, 34 clinical cure was reported for the majority of patients with cavernous DAVFs after SRS. In one study of 20 patients with cavernous DAVFs (mainly Type D), 4 symptomatic improvement was reported in 19 of 20 cases, with 15 of 18 patients with ocular symptoms demonstrating complete resolution of their symptoms. 25 In the largest study of SRS for DAVF, 34 146 cavernous DAVFs were treated at a mean marginal dose of 17.2 Gy. Fifty-seven of 64 patients had complete resolution of preoperative cranial nerve palsies; the remaining 7 patients had ultimate clinical improvement. Only 1 patient developed a new permanent cranial nerve palsy. Transient worsening of visual symptoms was reported for 14 (10%) of 146 cases. Thrombosis of the superior ophthalmic vein was reported in 11 (7.5%) of 146 cases, although only 2 patients had resultant visual deterioration. In this study, radiographic cure rates for cavernous DAVFs were 75% as compared with 50% for noncavernous DAVFs. 34 Improved obliteration rates observed for cavernous DAVFs as compared with transverse-sigmoid DAVFs may be confounded by generally smaller treatment volumes in the former group.
9,10 A known positive prognostic factor for AVM obliteration after SRS, 24, 26 obliteration as a function of smaller DAVF size was only specifically addressed in one study. 7 In this study, the obliteration rate was 75% for DAVFs smaller than or equal to 10 mm, decreasing to 64% for those larger than 10 mm. Indeed, this study concluded that the 2 main statistically significant factors negatively influencing DAVF obliteration were CVD and target size greater than 20 mm. Across our review, the study with the highest mean treatment volume (9.6 cm 3 ) demonstrated the lowest overall obliteration rate (41%). 9 On the other hand, the study of Onizuka et al. 20 reported a 100% obliteration rate for 4 cavernous DAVFs with treatment volumes ranging from 0.8 to 1.8 cm 3 . Thus, in addition to cavernous location and lack of CVD, small DAVF size likely improves obliteration rates after SRS.
Conclusions
Stereotatic radiosurgery with or without adjunctive embolization is an effective therapy for DAVFs that are not amenable to surgical or endovascular monotherapy. Including our own data, a review across 14 series revealed an overall obliteration rate of 71%. Transient worsening occurred in 9.1% of patients, permanent worsening in 2.4%, and post-SRS hemorrhage in 1.6% of cases (4.8% of those with CVD). Stereotactic radiosurgery is best suited for lesions without CVD and for low-flow cavernous DAVFs, demonstrating obliteration rates of 80% and 84%, respectively, and lower long-term complication rates.
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